BAYZED HEALTH: 2025 Annual Report

HKEXApr 30 21:52 · Announcements

Baize Medical (2609.HK) solidifies its foundation with steady profit growth, while strategic upgrades pave the way for new growth pathways.

The year 2025 represents a period of profound turbulence for the private oncology medical sector. On one hand, the industry is experiencing accelerated differentiation and the exit of some institutions, while on the other hand, the market scale continues to expand. Against this backdrop, Baize Medical (2609.HK), which has been listed for only half a year, released its first annual performance report, showing clear signs of economic improvement. In the author's view, its growth momentum primarily stems from three aspects: enhancement in financial quality, optimization of operational structure, and upgrading of strategic positioning. 1. Quality signals behind the financial figures From a performance perspective, Baize Medical achieved revenue of 1.12 billion yuan in 2025, with an adjusted net profit reaching 17.9 million yuan, an

Gelonghui FinanceApr 3 11:09

Bayzed Health Narrows Loss in 2025; Shares Jump 15%

MT NewswiresApr 1 14:08

Bayzed Health Swings to Deeper Loss but Boosts Cash and Cuts Leverage in 2025

TipRanksApr 1 04:57

Baize Medical (02609.HK) 2025 Annual Results: Adjusted Profit Surges 43%, Cash Reserves Exceed 600 Million, Strengthening Full-cycle Oncology Services

Gelonghui, March 31 | Baize Medical (02609.HK) announced its annual performance. In the fiscal year 2025, the group achieved revenue of approximately RMB 1.1198 billion. Hospital business revenue amounted to approximately RMB 915 million, of which tumor-related revenue was about RMB 440 million, accounting for approximately 48.1%. The adjusted profit was approximately RMB 17.9 million, representing a year-on-year increase of about 43.2%; operating net cash flow reached approximately RMB 222 million, marking a year-on-year growth of 32.0%, setting a new historical high; the asset-liability ratio significantly decreased from 46.9% at the end of 2024 to approximately 36.6%, with continuous optimization of the asset-liability structure.

Gelonghui FinanceMar 31 22:18

BAYZED HEALTH: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2025

HKEXMar 31 22:09 · Announcements